Home › Research › Treatments
Quality Gaps in Online Media Coverage of Antiamyloid Monoclonal Antibodies for Alzheimer Disease
Arthur C. Macedo, Albuquerque Lima, Isabela Sheng Ling Miaw, Isabella Harb Bizzi, Jesus Mística Ventura Balbino, Joseph Therriault, Eduardo Rigon Zimmer, Pietro Ghezzi et al.. JAMA Network Open, 2026-03-31
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This cross-sectional study examines the quality of information on Alzheimer disease (AD) monoclonal antibodies presented by news websites.
What this study adds
Evidence grade: Low
This is a cross-sectional study. This cross-sectional study examines the quality of information about Alzheimer disease monoclonal antibodies presented by news websites. It does not test any treatment, so it shows nothing about treating, curing or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Macedo, A. C., Lima, A., Miaw, I. S. L., Bizzi, I. H., Balbino, J. M. V., Therriault, J., et al. (2026). Quality Gaps in Online Media Coverage of Antiamyloid Monoclonal Antibodies for Alzheimer Disease. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.5026
Vancouver
Macedo AC, Lima A, Miaw ISL, Bizzi IH, Balbino JMV, Therriault J, et al. Quality Gaps in Online Media Coverage of Antiamyloid Monoclonal Antibodies for Alzheimer Disease. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.5026. PMID: 41915395.
BibTeX
@article{macedo2026-41915395,
author = {Macedo, Arthur C. and Lima, Albuquerque and Miaw, Isabela Sheng Ling and Bizzi, Isabella Harb and Balbino, Jesus Mística Ventura and Therriault, Joseph and Zimmer, Eduardo Rigon and Ghezzi, Pietro and others},
title = {{Quality Gaps in Online Media Coverage of Antiamyloid Monoclonal Antibodies for Alzheimer Disease}},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.5026},
pmid = {41915395},
url = {https://doi.org/10.1001/jamanetworkopen.2026.5026}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- This cross-sectional study examines the quality of information on Alzheimer disease (AD) monoclonal antibodies presented by news websites.
Why it matters
This cross-sectional study examines the quality of information about Alzheimer disease monoclonal antibodies presented by news websites. It does not test any treatment, so it shows nothing about treating, curing or preventing the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 42/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Network Open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Pedro Rosa‐Neto: h-index 89 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41915395) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2026.5026
- PubMed: 41915395
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.